Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopenia
Despite the common consideration of marked preexisting thrombocytopenia as a contraindication for RLT, this study indicates feasibility of PSMA-RLT in patients with preexisting thrombocytopenia of grade ≥ 2, as in our preliminary experience, there was no RLT-induced significant deterioration of platelet cell count. Thus, patients with thrombocytopenia should not be categorically excluded from receiving PSMA-RLT.
Authors
- Caroline Burgard (ORCID: https://orcid.org/0000-0003-1522-8860)
- Arne Blickle (ORCID: https://orcid.org/0009-0009-2460-7249)
- Samer Ezziddin (ORCID: https://orcid.org/0000-0003-4110-3375)
- Stephan Maus (ORCID: https://orcid.org/0000-0003-1679-8080)
- Maike Sieben
- Mark Bartholomä (ORCID: https://orcid.org/0000-0002-0361-2833)
- Moritz B. Bastian
- Andrea Schaefer-Schuler (ORCID: https://orcid.org/0000-0002-2439-5786)
- Florian Rosar (ORCID: https://orcid.org/0000-0002-2985-4099)
- Tilman Speicher
Institutions
- Saarland University (DE)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1007/s00259-024-07006-z
- Citations
- 4
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Universität des Saarlandes